2nd Mar 2016 08:25
LONDON (Alliance News) - Hutchison China MediTech Ltd said Wednesday its Hutchison MediPharma Ltd drug research and development subsidiary has started a phase two trial in China on patients with thyroid cancer.
The pharmaceutical company said the trial will focus on its sulfatinib drug, evaluating its efficacy and safety in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer, or patients with medullary thyroid cancer.
Hutchison said it plans to enroll 50 patients in total, consisting of 25 patients with each tumor type. It said it hopes the trial will prove its sulfatinib drug inhibits tumor growth, adding the trial is taking place in China as there are few safe and effective treatment options for China's patient population.
Shares in Hutchison were up 0.9% at 2,355.30 pence on Wednesday.
By Hannah Boland; [email protected]; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed